Table 2.
RITs targeting solid tumors
| Target antigen | RIT | Toxins | Indication | Phase | References |
|---|---|---|---|---|---|
| MSLN | SS1P | PE38 | Mesothelioma | II | 139–141, 143 |
| Ovarian antigen | OVB3-PE | Entire PE | Refractory ovarian cancer | I | 144 |
| CD25 | LMB-2 | PE38 | Metastatic melanoma | I | 145 |
| ErbB2 | ERB-38 | PE38 | Breast cancer | I | 153 |
| ScFv(FRP5)-ETA | PE | Metastatic breast cancers, colorectal cancers, malignant melanoma | I | 160 | |
| Lewis Y | LMB-1 | PE38 | Epithelial tumors | I | 162 |
| SGN-10 | PE40 | Metastatic carcinoma | I | 166 | |
| IL-4R | NBI-3001 | PE38 | Malignant gliomas | I | 171, 172 |
| EpCAM | VB4-845 | PE | Transitional cell carcinoma | I | 179 |
Abbreviations: RITs, recombinant immunotoxins; PE, Pseudomonas exotoxin; MSLN, mesothelin; IL, interleukin; EpCAM, epithelial cell adhesion molecule.